Ability Neurotech approved to start its first long-term BCI implant study in ALS
The Dutch-approved study at UMC Utrecht will test a fully implanted, battery-free wireless ECoG BCI for communication at home.
Ability Neurotech has received approval from a Dutch medical research ethics committee to begin the first chronic implantation study of its fully implantable, battery-free wireless BCI, in people with ALS. The study will run at UMC Utrecht with partners at Graz University of Technology and CorTec. The aim is a home-use system that restores communication by generating text from brain signals. The device records ECoG and transmits data through the skin over a 50 Mb/s optical link.
Ability recorded from the human brain for the first time two months later, in an intraoperative study in Munich (our coverage).
Learn more: Speech neuroprosthesis · UMC Utrecht Brain Center